Inspire Medical Systems, Inc. (NYSE:INSP) Q1 2024 Earnings Call Transcript

And the higher BMI patients have more of a lateral wall collapse, hypoglossal nerve stimulation is designed to treat tongue base obstruction, not lateral wall collapse. So we know as the patients get a higher BMI that the GLP-1s can be complementary to bring them to a lower BMI and relax the lateral walls. And to your question, the belief is, and I think what you’ll see from the SURMOUN-OSA trial is patients who have a lower BMI do not have the same level of AHI reduction simply by the fact that mechanism, they don’t have lateral wall collapse and GLP-1 are not designed to treat tongue base collapse, that’s what Inspire does. That’s how the two become complementary to each other. So thanks very much for that, Suraj.

Operator: This concludes the Q&A session for the conference. I’d now like to turn it back to Tim for closing remarks.

Tim Herbert: Thank you all for joining the call today. As always, I’m grateful to the growing team of dedicated Inspire employees for their enthusiasm, hard work and continued motivation to achieve successful and consistent patient outcomes. The team’s commitment to the patients remains unmatched and is the most important element to our success. I wish to thank all of our employees as well as the healthcare teams for their continued efforts as we remain focused on further expanding our business in the US, Europe and Asia. For all of you on the call, we appreciate your continued interest and support of Inspire. We look forward to providing you with further updates in the months ahead. Thank you all very much.

Operator: This concludes today’s conference call. You may now disconnect.